ARS Pharmaceuticals, Inc. SPRY

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences. Wells Fargo Healthcare Conference 1x1 Investor Meetings: Wednesday, September 9, 2026Location: Boston Cantor Global Healthcare Conference Fireside Chat: Fr

On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous urticaria. The quarter itself showed a company still early in proving […]

Moby summary of ARS Pharmaceuticals, Inc.'s Q2 2026 earnings call

CEO Donn Casale outlines path to cash flow breakeven by 2027 while navigating slower-than-expected adoption and manufacturing headwinds.

$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 2026 and supporting an expected path to cash flow breakeven by the end of 2027 Commercial operations strengthened with appointment of Meg Smith as Chief Commercial Officer and completed expansion of field sal

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strate

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company’s Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company’s current President, has […]

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which c

In late June 2026, ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) was removed from both the Russell 2000 Growth-Defensive Index and the Russell 2000 Defensive Index, altering its presence in widely followed small-cap benchmarks. This dual index removal could affect the company’s visibility and index-linked ownership, prompting investors to reassess how they monitor and access ARS Pharmaceuticals’ stock. We’ll now examine how ARS Pharmaceuticals’ removal from key Russell 2000 defensive indices...

AI chip rally powers gains as inflation data looms.

The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.

Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage.